Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Net Margin (2016 - 2020)

KalVista Pharmaceuticals' Net Margin history spans 7 years, with the latest figure at 224.71% for Q2 2020.

  • For Q2 2020, Net Margin rose 14709.0% year-over-year to 224.71%; the TTM value through Jan 2021 reached 1252.22%, down 90462.0%, while the annual FY2025 figure was 1642.94%, 189623.0% up from the prior year.
  • Net Margin for Q2 2020 was 224.71% at KalVista Pharmaceuticals, up from 783.26% in the prior quarter.
  • Across five years, Net Margin topped out at 13.57% in Q2 2018 and bottomed at 5133.33% in Q3 2017.
  • The 5-year median for Net Margin is 319.09% (2019), against an average of 1098.34%.
  • The largest annual shift saw Net Margin tumbled -467436bps in 2017 before it skyrocketed 494721bps in 2018.
  • A 5-year view of Net Margin shows it stood at 2152.79% in 2016, then soared by 79bps to 442.41% in 2017, then soared by 81bps to 83.85% in 2018, then plummeted by -167bps to 224.08% in 2019, then decreased by 0bps to 224.71% in 2020.
  • Per Business Quant, the three most recent readings for KALV's Net Margin are 224.71% (Q2 2020), 783.26% (Q1 2020), and 224.08% (Q4 2019).